Table 9 Kidney
Author | Cases N | Controlsa/Cohortb | Source Population | Exposure definition | Exposure assessment | Drug | RR | 95% CI |
|---|---|---|---|---|---|---|---|---|
McLaughlin et al. [63] | 495* | 697a | Population based | More than 14 times per month for >36 months | Personal Interview | Aspirin (8%) | 0.5†| 0.2–1.0 |
|  |  |  |  |  |  |  | 1.8‡ | 0.7–4.1 |
McCredie et al. 1988[64] | 360* | 985a | Population based | >0.1 kg lifetime use | Mailed questionnaire | Aspirin (18%) | 1.2 | 0.7–1.9 |
McCredie et al.1995[65] | 1,732* | 2,309a | Population based | >5 kg lifetime use | Personal Interview | Aspirin (5%) | 1.2 | 0.9–1.7 |
Gago-Dominguez et al. [66] | 1,201* | 1,204a | Population based | Two or more times a week for 1 month or longer | Personal Interview | Aspirin (27%) | 1.5 | 1.2–1.8 |
Paganini-Hill et al. [40] | NR* | 13,987b | Cohort | Daily use of aspirin for an undefined time | Mailed Questionnaire | Aspirin (16%) | 6.3 | 2.0–20.0 |
Schreinemachers et al. [43] | 32 | 12,668b | Cohort | Ever use of aspirin in the 30 days prior to start date | Personal Interview | Aspirin (59%) | 0.60 | 0.29–1.24 |
- *Renal cell carcinoma only;
Prevalence of exposure among controls/cohort; †Male only; ‡Female only.